<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="958">
  <stage>Registered</stage>
  <submitdate>3/05/2006</submitdate>
  <approvaldate>3/05/2006</approvaldate>
  <actrnumber>ACTRN12606000154505</actrnumber>
  <trial_identification>
    <studytitle>A Phase I Single Dose Pharmacokinetic Study of DG17 versus DG17 in combination with ritonavir in Healthy Subjects</studytitle>
    <scientifictitle>A Phase I Single Dose Pharmacokinetic Study of DG17 versus DG17 in combination with Ritonavir in healthy subjects</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Healthy subjects</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral 100mg or 200mg of DG17 with 100mg of oral Ritonavir, single dose. Wash-out period is 1 week.</interventions>
    <comparator>Oral 100mg or 200mg of DG17 without 100mg of oral Ritonavir, single dose.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood level of DG35 (active drug)</outcome>
      <timepoint>At 0, 15, 30, 45, 60, 90, 120, 150, 180, 240, 360, 480, 600 and 720 min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>No secondary outcome</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Able to provide written informed consent· Able to comply with the requirements of the study· Able to provide a permanent residential address· Judged as healthy by medical history, physical examination and laboratory screening within 21 days of study entry· Test negative for HIV, hepatitis B and C· No evidence of drug or alcohol abuse· Willing to abstain from taking any prescription or over-the-counter medication while in the clinical trial  all health supplements were discontinued at least 7 days before the first treatment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Recent (within the last 12 months) of a serious medical illness or medical disorder· Subject currently taking prescription medications of any type, or non-prescription antacids (alkalis, H2 or proton pump inhibitors)· Current infection· Abnormal findings on physical examination· Abnormal screening laboratory values considered significant by the investigator· Donation of blood within the last 30 days· Participation in another clinical trial within the last 30 days· History of alcohol or drug abuse· Cigarette smokers.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Computer generated</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>12/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>18</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Narhex Life Sciences Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Narhex Life Sciences Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Alfred Hospital Melbourne</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To study the pharmacokinetics of DG17 absorption.  DG17 is a novel protease inhibitor for the treatment of HIV.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital (Melbourne)</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/12/2005</ethicapprovaldate>
      <hrec>228/05</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof. Henry Krum</name>
      <address>NHMRC Centre of Clinical Research Excellence in Therapeutics
Faculty of Medicine, Nursing and Health Sciences
3rd floor, Burnet tower, AMREP Precinct
89 Commercial Rd., Melbourne VIC 3004</address>
      <phone>+61 3 99030042</phone>
      <fax>+61 3 99030556</fax>
      <email>henry.krum@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof. John Mills</name>
      <address>Alfred Hospital
Faculty of Medicine, Nursing and Health Sciences
Commercial Rd., Melbourne, VIC 3004</address>
      <phone>+61 3 99030677</phone>
      <fax>+61 3 95212124</fax>
      <email>mills@portsea.net</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>